VILDAPRIDE DM 500

About

VILDAPRIDE DM 500 is a combination medication indicated for the treatment of type 2 diabetes mellitus. It comprises Vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, and Metformin, a biguanide. Vildagliptin works by inhibiting the breakdown of incretin hormones, leading to increased insulin secretion from pancreatic beta cells and decreased glucagon secretion from alpha cells, both in a glucose-dependent manner. Metformin primarily reduces glucose production in the liver, decreases intestinal glucose absorption, and enhances insulin sensitivity in peripheral tissues. This synergistic action addresses multiple pathophysiological defects in type 2 diabetes, resulting in improved glycemic control and a reduction in both fasting and post-prandial blood glucose levels.

Uses

• Treatment of type 2 diabetes mellitus.
• As an adjunct to diet and exercise.
• When monotherapy with Metformin or Vildagliptin is insufficient.
• To improve glycemic control in adults.

Directions For Use

Take orally, usually with meals to minimize gastrointestinal upset. Follow your doctor's prescribed dosage and schedule strictly.

Benefits

• Improved HbA1c levels.
• Dual mechanism of action for comprehensive control.
• Reduced fasting and post-prandial glucose.
• Potential for weight neutrality or modest weight loss.
• Lower risk of hypoglycemia compared to sulfonylureas.
• Convenient combination therapy.

Side Effects

• Nausea
• Vomiting
• Diarrhea
• Abdominal pain
• Metallic taste
• Headache
• Dizziness
• Nasopharyngitis
• Joint pain
• Skin rash
• Fatigue
• Lactic acidosis (rare but serious)

Safety Measures

• Alcohol - Avoid excessive alcohol consumption due to increased risk of lactic acidosis, especially with Metformin.
• Pregnancy - Generally not recommended during pregnancy; consult a doctor. Use only if potential benefits outweigh risks.
• Breastfeeding - Not recommended as components may pass into breast milk. Consult a healthcare professional.
• Liver - Use with caution; Metformin is contraindicated in severe hepatic impairment. Vildagliptin may require dose adjustment.
• Kidney - Metformin is contraindicated in severe renal impairment (eGFR <30 mL/min/1.73m²). Vildagliptin requires dose adjustment based on renal function.
• Lung - Severe respiratory insufficiency can increase the risk of lactic acidosis with Metformin.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.